Skip to content

Study · Not a test of the peptide alone · 2024

6 results

Glucagon-like peptide receptor agonists and risk for depression.

Tagliapietra GA, Cantrell MA, Lund BC

Primary care diabetes8 Jun 2024Cited by 15 (Europe PMC)

PMID38852027 (opens in a new tab)DOI10.1016/j.pcd.2024.05.005 (opens in a new tab)PepBankPUB-38852027
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In US veterans, crude incident depression within 1 year was 7.7% after starting a GLP-1RA class drug and 6.3% after starting a DPP-4 inhibitor.

    In plain wordsIn US veterans, 7.7% of people starting GLP-1 drugs and 6.3% starting DPP-4 inhibitors had depression within a year, before adjustment.

    Peptide
    Liraglutide
    Outcome
    IncreaseIncident depression within 1 year
    Study

    n = 139,608

    Comparator
    DPP-4 inhibitors
    Analysis
    Primary
    Outcome group
    Anxiety and mood · Mental health and mood

    Measurements

    Incident depression
    7.7%
    GLP-1RA
    Incident depression
    6.3%
    DPP-4i

    Source sentences

    Summary
    Of 34,130 patients initiated on a GLP-1RA and 105,478 initiated on a DPP-4i, incident depression occurred in 7.7 % (n= 2263) and 6.3 % (n= 6602), respectively.
    1 context sentence
    Summary · context
    This retrospective cohort study compared Veterans Health Administration patients initiated on a GLP-1RA versus a dipeptidyl peptidase-4 inhibitor (DPP-4i) between June 1, 2013 and June 30, 2020.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In US veterans, crude incident depression within 1 year was 7.7% after starting a GLP-1RA class drug and 6.3% after starting a DPP-4 inhibitor.

    In plain wordsIn US veterans, 7.7% of people starting GLP-1 drugs and 6.3% starting DPP-4 inhibitors had depression within a year, before adjustment.

    Peptide
    Semaglutide
    Outcome
    IncreaseIncident depression within 1 year
    Study

    n = 139,608

    Comparator
    DPP-4 inhibitors
    Analysis
    Primary
    Outcome group
    Anxiety and mood · Mental health and mood

    Measurements

    Incident depression
    7.7%
    GLP-1RA
    Incident depression
    6.3%
    DPP-4i

    Source sentences

    Summary
    Of 34,130 patients initiated on a GLP-1RA and 105,478 initiated on a DPP-4i, incident depression occurred in 7.7 % (n= 2263) and 6.3 % (n= 6602), respectively.
    1 context sentence
    Summary · context
    This retrospective cohort study compared Veterans Health Administration patients initiated on a GLP-1RA versus a dipeptidyl peptidase-4 inhibitor (DPP-4i) between June 1, 2013 and June 30, 2020.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In US veterans, GLP-1RA class initiation did not significantly raise the adjusted risk of incident depression versus DPP-4 inhibitors (relative risk 1.02, 95% CI 0.97 - 1.07).

    In plain wordsIn US veterans, starting GLP-1 drugs was not linked to a clear rise in depression compared with DPP-4 inhibitors.

    Peptide
    Liraglutide
    Outcome
    No significant changeIncident depression within 1 year
    Study

    n: not reported in source

    Comparator
    DPP-4 inhibitors
    Analysis
    Primary
    Outcome group
    Anxiety and mood · Mental health and mood

    Measurements

    Adjusted relative risk
    1.02
    GLP-1RA vs DPP-4i

    Source sentences

    Summary
    After adjustment, the relative risk was 1.02 (95 % CI: 0.97 - 1.07), thus failing to demonstrate a significant increase in risk for incident depression following initiation of a GLP-1RA compared to DPP-4i.
    1 context sentence
    Summary · context
    This retrospective cohort study compared Veterans Health Administration patients initiated on a GLP-1RA versus a dipeptidyl peptidase-4 inhibitor (DPP-4i) between June 1, 2013 and June 30, 2020.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In US veterans, GLP-1RA class initiation did not significantly raise the adjusted risk of incident depression versus DPP-4 inhibitors (relative risk 1.02, 95% CI 0.97 - 1.07).

    In plain wordsIn US veterans, starting GLP-1 drugs was not linked to a clear rise in depression compared with DPP-4 inhibitors.

    Peptide
    Semaglutide
    Outcome
    No significant changeIncident depression within 1 year
    Study

    n: not reported in source

    Comparator
    DPP-4 inhibitors
    Analysis
    Primary
    Outcome group
    Anxiety and mood · Mental health and mood

    Measurements

    Adjusted relative risk
    1.02
    GLP-1RA vs DPP-4i

    Source sentences

    Summary
    After adjustment, the relative risk was 1.02 (95 % CI: 0.97 - 1.07), thus failing to demonstrate a significant increase in risk for incident depression following initiation of a GLP-1RA compared to DPP-4i.
    1 context sentence
    Summary · context
    This retrospective cohort study compared Veterans Health Administration patients initiated on a GLP-1RA versus a dipeptidyl peptidase-4 inhibitor (DPP-4i) between June 1, 2013 and June 30, 2020.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 05HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In US veterans, relative risk estimates for incident depression with GLP-1RA class drugs versus DPP-4 inhibitors were non-significant in all sensitivity analyses.

    In plain wordsIn US veterans, extra checks also found no clear link between GLP-1 drugs and depression compared with DPP-4 inhibitors.

    Peptide
    Liraglutide
    Outcome
    No significant changeIncident depression within 1 year
    Study

    n: not reported in source

    Comparator
    DPP-4 inhibitors
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    Relative risk estimates in all sensitivity analyses were also non-significant.
    1 context sentence
    Summary · context
    This retrospective cohort study compared Veterans Health Administration patients initiated on a GLP-1RA versus a dipeptidyl peptidase-4 inhibitor (DPP-4i) between June 1, 2013 and June 30, 2020.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In US veterans, relative risk estimates for incident depression with GLP-1RA class drugs versus DPP-4 inhibitors were non-significant in all sensitivity analyses.

    In plain wordsIn US veterans, extra checks also found no clear link between GLP-1 drugs and depression compared with DPP-4 inhibitors.

    Peptide
    Semaglutide
    Outcome
    No significant changeIncident depression within 1 year
    Study

    n: not reported in source

    Comparator
    DPP-4 inhibitors
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    Relative risk estimates in all sensitivity analyses were also non-significant.
    1 context sentence
    Summary · context
    This retrospective cohort study compared Veterans Health Administration patients initiated on a GLP-1RA versus a dipeptidyl peptidase-4 inhibitor (DPP-4i) between June 1, 2013 and June 30, 2020.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.